New Insights into the Immunopathology and Control of Dengue Virus Infection

Overview

Journal Nat Rev Immunol

Specialty Allergy & Immunology

Date 2015 Nov 26

PMID 26603900

Citations 175

Authors

Gavin Screaton

Juthathip Mongkolsapaya

Sophie Yacoub

Catherine Roberts

Affiliations

Soon will be listed here.

Abstract

Dengue virus poses a major threat to global public health: two-thirds of the world's population is now at risk from infection by this mosquito-borne virus. Dengue virus causes a range of diseases with a small proportion of infected patients developing severe plasma leakage that leads to dengue shock syndrome, organ impairment and bleeding. Infection with one of the four viral serotypes results in the development of homotypic immunity to that serotype. However, subsequent infection with a different serotype is associated with an increased risk of developing severe disease, which has led to the suggestion that severe disease is triggered by immunopathology. This Review outlines recent advances in the understanding of immunopathology, vaccine development and human monoclonal antibodies produced against dengue virus.

Citing Articles

Anakinra for dengue patients with hyperinflammation: protocol for a randomized double-blind placebo-controlled trial.

Huyen T, Trieu H, Vuong N, Minh Nguyet N, Tam D, McBride A Wellcome Open Res. 2025; 9:689.

PMID: 39931105 PMC: 11809184. DOI: 10.12688/wellcomeopenres.21017.1.

Dengue virus infection: how platelet-leukocyte crosstalk shapes thrombotic events and inflammation.

Amin A, Nikdoust F, Khorram S, Marashi S, Ghanavati P, Ameri F Mol Biol Rep. 2025; 52(1):119.

PMID: 39804486 DOI: 10.1007/s11033-025-10222-x.

Assessing the Diagnostic Value of Mean Monocyte Volume and Hematological Parameters in Predicting Dengue Fever: A Cross-Sectional Analysis.

Ismail N, Siddig A, Ab Aziz N, Ramli M, Zulkafli Z, Johan M Cureus. 2025; 16(12):e75174.

PMID: 39759638 PMC: 11700026. DOI: 10.7759/cureus.75174.

Molecular detection of dengue virus from febrile patients in Ghana.

Bonney J, Pratt D, Ofori M, Hayashi T, Abankwa A, Awuku-Larbi Y BMC Infect Dis. 2024; 24(1):1382.

PMID: 39627698 PMC: 11616235. DOI: 10.1186/s12879-024-10289-0.

Dengue Virus Infection: Immune Response and Therapeutic Targets.

Tin Ern N, Komarasamy T, Adnan N, Balasubramaniam V Am J Trop Med Hyg. 2024; 112(1):37-44.

PMID: 39531732 PMC: 11720763. DOI: 10.4269/ajtmh.23-0545.

References

Olkowski S, Forshey B, Morrison A, Rocha C, Vilcarromero S, Halsey E . Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis. 2013; 208(6):1026-33. PMC: 3749012. DOI: 10.1093/infdis/jit273. View

Fibriansah G, Ibarra K, Ng T, Smith S, Tan J, Lim X . DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science. 2015; 349(6243):88-91. PMC: 4672004. DOI: 10.1126/science.aaa8651. View

Cherrier M, Kaufmann B, Nybakken G, Lok S, Warren J, Chen B . Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J. 2009; 28(20):3269-76. PMC: 2771083. DOI: 10.1038/emboj.2009.245. View

Halstead S, Udomsakdi S, Simasthien P, Singharaj P, Sukhavachana P, Nisalak A . Observations related to pathogenesis of dengue hemorrhagic fever. I. Experience with classification of dengue viruses. Yale J Biol Med. 1970; 42(5):261-75. PMC: 2591684. View

Zompi S, Santich B, Beatty P, Harris E . Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J Immunol. 2011; 188(1):404-16. PMC: 3244532. DOI: 10.4049/jimmunol.1102124. View

Fibriansah G, Tan J, Smith S, de Alwis A, Ng T, Kostyuchenko V . A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol Med. 2014; 6(3):358-71. PMC: 3958310. DOI: 10.1002/emmm.201303404. View

Ramachandran G . Gram-positive and gram-negative bacterial toxins in sepsis: a brief review. Virulence. 2013; 5(1):213-8. PMC: 3916377. DOI: 10.4161/viru.27024. View

Guzman M, Alvarez M, Rodriguez-Roche R, Bernardo L, Montes T, Vazquez S . Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis. 2007; 13(2):282-6. PMC: 2725871. DOI: 10.3201/eid1302.060539. View

Sun W, Cunningham D, Wasserman S, Perry J, Putnak J, Eckels K . Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults. Hum Vaccin. 2008; 5(1):33-40. DOI: 10.4161/hv.5.1.6348. View

10.

Shrestha B, Brien J, Sukupolvi-Petty S, Austin S, Edeling M, Kim T . The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. 2010; 6(4):e1000823. PMC: 2848552. DOI: 10.1371/journal.ppat.1000823. View

11.

Yu X, McGraw P, House F, Crowe Jr J . An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies. J Immunol Methods. 2008; 336(2):142-51. PMC: 2519117. DOI: 10.1016/j.jim.2008.04.008. View

12.

Sukupolvi-Petty S, Austin S, Engle M, Brien J, Dowd K, Williams K . Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol. 2010; 84(18):9227-39. PMC: 2937608. DOI: 10.1128/JVI.01087-10. View

13.

Durbin A, Kirkpatrick B, Pierce K, Elwood D, Larsson C, Lindow J . A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis. 2013; 207(6):957-65. PMC: 3571448. DOI: 10.1093/infdis/jis936. View

14.

Hadinegoro S, Arredondo-Garcia J, Capeding M, Deseda C, Chotpitayasunondh T, Dietze R . Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med. 2015; 373(13):1195-206. DOI: 10.1056/NEJMoa1506223. View

15.

McLellan J, Chen M, Leung S, Graepel K, Du X, Yang Y . Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013; 340(6136):1113-7. PMC: 4459498. DOI: 10.1126/science.1234914. View

16.

Libraty D, Young P, Pickering D, Endy T, Kalayanarooj S, Green S . High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis. 2002; 186(8):1165-8. DOI: 10.1086/343813. View

17.

Zellweger R, Tang W, Eddy W, King K, Sanchez M, Shresta S . CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice. J Virol. 2015; 89(12):6494-505. PMC: 4474296. DOI: 10.1128/JVI.00036-15. View

18.

Garcia G, Sierra B, Perez A, Aguirre E, Rosado I, Gonzalez N . Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcgammaRIIa polymorphism. Am J Trop Med Hyg. 2010; 82(6):1153-6. PMC: 2877427. DOI: 10.4269/ajtmh.2010.09-0353. View

19.

Gromowski G, Barrett N, Barrett A . Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol. 2008; 82(17):8828-37. PMC: 2519678. DOI: 10.1128/JVI.00606-08. View

20.

Lok S, Kostyuchenko V, Nybakken G, Holdaway H, Battisti A, Sukupolvi-Petty S . Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol. 2008; 15(3):312-7. DOI: 10.1038/nsmb.1382. View